Back to Search
Start Over
Volumetric Analysis of Glioblastoma for Determining Which CpG Sites Should Be Tested by Pyrosequencing to Predict Temozolomide Efficacy.
- Source :
-
Biomolecules [Biomolecules] 2022 Sep 26; Vol. 12 (10). Date of Electronic Publication: 2022 Sep 26. - Publication Year :
- 2022
-
Abstract
- The aim of the present study was to determine which individual or combined CpG sites among O <superscript>6</superscript> -methylguanine DNA methyltransferase CpG 74-89 in glioblastoma mainly affects the response to temozolomide resulting from CpG methylation using statistical analyses focused on the tumor volume ratio (TVR). We retrospectively examined 44 patients who had postoperative volumetrically measurable residual tumor tissue and received adjuvant temozolomide therapy for at least 6 months after initial chemoradiotherapy. TVR was defined as the tumor volume 6 months after the initial chemoradiotherapy divided by that before the start of chemoradiotherapy. Predictive values for TVR as a response to adjuvant therapy were compared among the averaged methylation percentages of individual or combined CpGs using the receiver operating characteristic curve. Our data revealed that combined CpG 78 and 79 showed a high area under the curve (AUC) and a positive likelihood ratio and that combined CpG 76-79 showed the highest AUC among all combinations. AUCs of consecutive CpG combinations tended to be higher for CpG 74-82 in exon 1 than for CpG 83-89 in intron 1. In conclusion, the methylation status at CpG sites in exon 1 was strongly associated with TVR reduction in glioblastoma.<br />Competing Interests: The authors declare no conflict of interest.
- Subjects :
- Humans
Temozolomide pharmacology
Temozolomide therapeutic use
Retrospective Studies
Antineoplastic Agents, Alkylating pharmacology
Antineoplastic Agents, Alkylating therapeutic use
DNA Methylation
DNA Repair Enzymes metabolism
High-Throughput Nucleotide Sequencing
DNA therapeutic use
Glioblastoma drug therapy
Glioblastoma genetics
Brain Neoplasms drug therapy
Brain Neoplasms genetics
Subjects
Details
- Language :
- English
- ISSN :
- 2218-273X
- Volume :
- 12
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Biomolecules
- Publication Type :
- Academic Journal
- Accession number :
- 36291588
- Full Text :
- https://doi.org/10.3390/biom12101379